Table 2. Baseline and follow-up cortical lesion volumes and counts in patients with primary progressive multiple sclerosis.
| Baseline (n = 25) | *p | Follow-up (n = 20) | **p | ***p | |
|---|---|---|---|---|---|
| CL number | |||||
| DIRTotal CL | 7.2 ± 6.8 (179) | 0.006 | 7.7 ± 6.7 (153) | 0.007 | n.s. |
| PSIR Total CL | 9.4 ± 9.1 (236) | 10.5 ± 9.5 (210) | 0.008 | ||
| DIR IC | 1.8 ± 2.0 (45) | n.s. | 1.8 ± 2.1 (35) | n.s. | n.s. |
| PSIR IC | 1.8 ± 1.96 (44) | 1.9 ± 2 (38) | n.s. | ||
| DIR LC | 5.4 ± 5.2 (134) | 0.003 | 5.9 ± 5.3 (118) | 0.003 | n.s. |
| PSIR LC | 7.7 ± 7.7 (192) | 8.6 ± 8.1 (172) | 0.014 | ||
| PSIR JC | 3.2 ± 3.97 (79) | - | 3.8 ± 4.3 (75) | - | n.s. |
| CL volume | |||||
| DIRTotal CLV | 0.46 ± 0.48 | n.s. | 0.54 ± 0.52 | n.s. | n.s. |
| PSIR Total CLV | 0.47 ± 0.45 | 0.50 ± 0.48 | n.s. | ||
| DIRICV | 0.11 ± 0.14 | n.s. | 0.10 ± 0.13 | n.s. | 0.036 |
| PSIR ICV | 0.06 ± 0.06 | 0.07 ± 0.08 | n.s. | ||
| DIRLCV | 0.35 ± 0.39 | n.s. | 0.44 ± 0.46 | n.s. | n.s. |
| PSIR LCV | 0.42 ± 0.43 | 0.44 ± 0.47 | n.s. | ||
| PSIR JCV | 0.18 ± 0.20 | - | 0.23 ± 0.20 | - | n.s. |
Values in table are: mean +/- standard deviation; lesion volumes are in cm3. in () = total number of lesions detected; DIR = double inversion recovery; PSIR = phase sensitive inversion recovery; CL = cortical lesions; IC = intracortical lesions; LC = leucocortical lesions; JC = juxtacortical lesions; CLV = cortical lesion volume; ICV = intracortical lesion volume; LCV = leucocortical lesion volume; JCV = juxtacortical lesion volume.
Wilcoxon signed-rank test p<0.05 was used to compare PSIR and DIR lesion counts and volumes in the MS cohort at baseline* and at follow-up**. ***Wilcoxon signed-rank test p<0.05 in 20 PPMS patients between baseline and follow-up.